ACET ▼ -0.1% - Adicet Bio, Inc. $ACET Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update Adicet Bio announced completion of the final patient visit for its planned interim analysis of prula-cel in systemic lupus erythematosus patients, along with a corporate update. The stock declined 0.1% following the announcement, suggesting investors may have been awaiting more substantive clinical data or results rather than a timeline milestone. 01-SEP-2026 07:00 AM ET